Text Size

Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation

This study has been terminated.
Sponsor:
Information provided by:
Procter and Gamble
ClinicalTrials.gov Identifier:
NCT00501241
First received: July 12, 2007
Last updated: June 16, 2009
Last verified: February 2008
History of Changes
  Purpose

The purpose of this study is to determine whether ATI-7505 is effective in the treatment of chronic idiopathic constipation.


Condition Intervention Phase
Chronic Constipation
 Drug: ATI-7505
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation

Resource links provided by NLM:

MedlinePlus related topics: Constipation
U.S. FDA Resources

Further study details as provided by Procter and Gamble:

Primary Outcome Measures:
  • Total number of spontaneous bowel movements during the first 7 days after randomization [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Daily and/or weekly assessments of the consistency, severity, frequency, symptoms of constipation during the treatment period [ Time Frame: daily and or weekly ] [ Designated as safety issue: No ]

Estimated Enrollment: 214
Study Start Date: July 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
placebo twice daily
 Drug: ATI-7505
Tablet,placebo, BID
Experimental: 2
20 mg ATI-7505, BID for 4 weeks
 Drug: ATI-7505
ATI-7505 20 mg BID for 4 weeks
Experimental: 3
40 mg ATI, BID, 4 weeks
 Drug: ATI-7505
tablet, 40 mg, BID, $ weeks
Experimental: 4
80 mg ATI-4505, BID for 4 weeks
 Drug: ATI-7505
80 mg ATI-7505, BID for 4 weeks
Experimental: 5
120 mg ATI-7505, BID for 4 weeks
 Drug: ATI-7505
120 mg ATI-7505, BID, for 4 weeks

Detailed Description:

This study is designed to evaluate the safety and efficacy of ATI 7505 in generally healthy, adult patients who have had symptoms of chronic idiopathic constipation for at least 6 months as defined in the ROME III criteria.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • written informed consent
  • 18 and 75 years of age
  • constipation symptom onset at least 6 months ago & meet ROME III criteria for chronic constipation
  • negative colonoscopy or air contrast barium enema within the past 2 years if ≥50 years of age or within the past 5 years if <50 years of age;
  • are able to refrain from use of medications known to treat constipation or associated symptoms throughout the study

Exclusion Criteria:

  • transabdominal surgery, unstable coronary artery disease, organic gastrointestinal disease, collagen vascular disease, or any alarm symptoms within the 6 months prior to screening;
  • taking prohibited medications (including laxatives, herbal remedies)
  • participating in another drug or medical device study or use of any investigational drug within 30 days before dosing or planning to use prior to study completion;
  • QTcB >440 msec, abnormal 12-lead ECG, family history of sudden death at age <40 years or history of long QT syndrome
  • alcohol or drug abuse within the 6 months prior to screening;
  • autonomic dyssynergic defecation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00501241

  Hide Study Locations
Locations
United States, California
Research Facility
Anaheim, California, United States
Research facility
San Carlos, California, United States
Research Facility
San Diego, California, United States
United States, Colorado
Research Facility
Littleton, Colorado, United States
United States, Florida
Research Facility
Aventura, Florida, United States
Research Facility
Hollywood, Florida, United States
Research Facility
South Miami, Florida, United States
United States, Georgia
Researrch Facility
Newnan, Georgia, United States
United States, Illinois
Research Facility
Rockford, Illinois, United States
United States, Indiana
Research Facility
Evansville, Indiana, United States
United States, Massachusetts
Research Facility
Boston, Massachusetts, United States
United States, New York
Research Facility
Great Neck, New York, United States
Research Facility
Lake Success, New York, United States
United States, Ohio
Research Facility
Cincinnati, Ohio, United States
United States, Oklahoma
Research Facility
Oklahoma City, Oklahoma, United States
United States, Tennessee
Research Facility
Chattanooga, Tennessee, United States
Research Facility
Nashville, Tennessee, United States
United States, Utah
Research Facility
Salt Lake City, Utah, United States
United States, Virginia
Research Facility
Charlottesville, Virginia, United States
Research Facility
Christiansburg, Virginia, United States
Canada, Quebec
Research Facility
Montreal, Quebec, Canada
Research Facility
St. Charles Borremee, Quebec, Canada
Canada
Reserach Facility
Quebec, Canada
Sponsors and Collaborators
Procter and Gamble
Investigators
Study Director: Tom G Todaro, MD Procter and Gamble
  More Information

No publications provided

Responsible Party: Tom Todaro, MD, Procter and Gamble Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00501241     History of Changes
Other Study ID Numbers: 2007003
Study First Received: July 12, 2007
Last Updated: June 16, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on May 16, 2013